Owing to technological development and decreasing cost of genetic testing, the NIPT market will grow significantly at 16.35% CAGR due to the availability of more genetic conditions. Non-Invasive Prenatal testing is widely adopted in the testing of common chromosomal aneuploidies and medical professionals believe that NIPT can be adopted in routine antenatal care.

The increasing prominence among pregnant women as it involves less risk in comparison to amniocentesis and increasing awareness about prenatal genetic issues will drive the growth of the global non-invasive prenatal testing (NIPT) market. The rising cases of miscarriage and complications will lead to a standard test in the future as it provides the precision of more than 99% and provides screening display in less time will create growth in the global non-invasive prenatal testing (NIPT) market.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/non-invasive-prenatal-testing-market/request-sample

The COVID-19 impact has a limited effect on the non-invasive prenatal testing market. According to the report by SeraCare, in-vitro diagnostics manufacturers and clinical testing laboratories have collaborated with research organisations to find out the SARS-CoV-2 infection on pregnant ladies and congenital disabilities in new-born. So there is a need for NIPT during COVID-19 outbreak.

Based on end-user, diagnostic laboratories dominate the NIPT market as there is a rising preference for using NIPT services of diagnostic laboratories by gynecologists and patients. Moreover, diagnostics labs have a well-equipped facility and skilled laboratory technicians resulting in a huge volume of tests being outsourced, thereby driving the growth of the market.

North America dominates the NIPT market owing to the rising incidences of genetic disorders in newborns, increasing awareness about NIPT, technological development in NIPT technologies, and increased spending on R&D activities will fuel the growth in the region.

Pacific Biosciences of California, Inc., has acquired Omniome, to expand its market opportunities for sequencing innovative ways and add value to customers. Omniome has a novel approach to have an accurate short-read sequencing platform and enter large, fast-growing clinical applications such as oncology and non-invasive prenatal testing.

The prominent players in the NIPT industry include GE Healthcare, Perkinelmer, Inc., Koninklijke N.V., Qiagen, Pacific Biosciences of California, Inc., Agilent Technologies, Inc., and Beijing Genomics Institute.

Source: VynZ Research

[email protected]